The DOI matches its Crossref record; 170 of the 170 references it cites were found in a registry or an index.
Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?
Abstract
Chronic kidney disease (CKD) is a worldwide public health problem associated with a high prevalence of cardiovascular disease (CVD) and impaired quality of life. Previous research for preventing loss of glomerular filtration rate (GFR) has focused on reducing blood pressure (BP) and proteinuria. Angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor antagonists (ARB) are commonly used in patients with early CKD, but their value in advanced CKD (estimated GFR (eGFR) ≤30 ml/min/1.73 m 2) is unknown. There remains a debate about the omission of ACEi/ARB in patients with advanced CKD and their use in association with CVD or heart failure. Does the potential gain in eGFR with ACEi/ARB cessation outweigh the potential adverse cardiovascular outcomes? This paper reviews the current literature that addresses this issue. Several controversies are discussed. Although lowering BP reduces cardiovascular events, evidence suggests that ACEi/ARBs are not superior to other antihypertensive agents. There are no studies assessing the benefits of ACEi/ARB therapy in cardiovascular risk reduction in advanced non-dialysis CKD. The STOP ACEi trial will strengthen the evidence base and shed light on the potential merits and dangers of ACEi/ARB use in advanced CKD on renal function and cardiovascular outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs104 · Cited by 6,879
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,121
Research works printed but not linked: 3
- 10.1159/000370275 · doi:10.1159/000370275
- 10.1093/ndt/gfq505 · doi:10.1093/ndt/gfq505
- 10.1159/000381477 · doi:10.1159/000381477
Cited by
Items 501–584 of 584
Phosphate intake, hyperphosphatemia, and kidney function
Rubio-Aliaga, I., & Krapf, R. (2022) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-022-02691-x · Cited by 65
Linkages between anxiety and outcomes in heart failure
De Jong, M. J., Chung, M. L., Wu, J.-R., Riegel, B., Rayens, M. K., & Moser, D. K. (2011) · Heart & Lung · doi:10.1016/j.hrtlng.2011.02.002 · Cited by 65
The metabolic syndrome and endothelial dysfunction: Common highway to type 2 diabetes and CVD?
Diamant, M., & Tushuizen, M. E. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0061-4 · Cited by 64
Toal, C. B., Meredith, P. A., & Elliott, H. L. (2012) · Blood Pressure · doi:10.3109/08037051.2012.690615 · Cited by 64
Hegele, R. A., Gidding, S. S., Ginsberg, H. N., McPherson, R., Raal, F. J., Rader, D. J., Robinson, J. G., & Welty, F. K. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306442 · Cited by 63
BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial
Leehey, D. J., Zhang, J. H., Emanuele, N. V., Whaley-Connell, A., Palevsky, P. M., Reilly, R. F., Guarino, P., & Fried, L. F. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02850315 · Cited by 62
β blockers in hypertension and cardiovascular disease
Ong, H. T. (2007) · BMJ · doi:10.1136/bmj.39185.440382.47 · Cited by 61
Thirty-Year Trends in Complications in U.S. Adults With Newly Diagnosed Type 2 Diabetes
Fang, M., & Selvin, E. (2021) · Diabetes Care · doi:10.2337/dc20-2304 · Cited by 59
Follistatin like 1 regulates hypertrophy in heart failure with preserved ejection fraction
Tanaka, K., Valero-Muñoz, M., Wilson, R. M., Essick, E. E., Fowler, C. T., Nakamura, K., van den Hoff, M., Ouchi, N., & Sam, F. (2016) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2016.04.002 · Cited by 59
Tinetti, M. E., McAvay, G., Trentalange, M., Cohen, A. B., & Allore, H. G. (2015) · BMJ · doi:10.1136/bmj.h4984 · Cited by 58
Nephroprotective effects of GLP-1 receptor agonists: where do we stand?
Mosterd, C. M., Bjornstad, P., & van Raalte, D. H. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00738-9 · Cited by 56
Digitalis for treatment of heart failure in patients in sinus rhythm
Hood Jr., W. B., Dans, A. L., Guyatt, G. H., Jaeschke, R., & McMurray, J. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002901.pub3 · Cited by 56
Initiative, O. B. O. T. C. F. D. C. A. P. C., Yarnoff, B. O., Hoerger, T. J., Simpson, S. K., Leib, A., Burrows, N. R., Shrestha, S. S., & Pavkov, M. E. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0497-6 · Cited by 55
Amraoui, F., Van Der Hoeven, N. V., Van Valkengoed, I. G. M., Vogt, L., & Van Den Born, B. H. (2014) · The Journal of Clinical Hypertension · doi:10.1111/jch.12243 · Cited by 53
Diabetic nephropathy: Time to withhold development and progression - A review
Sharaf El Din, U. A. A., Salem, M. M., & Abdulazim, D. O. (2017) · Journal of Advanced Research · doi:10.1016/j.jare.2017.04.004 · Cited by 53
Persson, F., Lindhardt, M., Rossing, P., & Parving, H.-H. (2016) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320316652047 · Cited by 54
Turner, M. E., Beck, L., Hill Gallant, K. M., Chen, Y., Moe, O. W., Kuro-o, M., Moe, S. M., & Aikawa, E. (2024) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.123.319198 · Cited by 54
Chen, Y.-Y., Lin, Y.-J., Chong, E., Chen, P.-C., Chao, T.-F., Chen, S.-A., & Chien, K.-L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123116 · Cited by 56
Makam, A. N., & Nguyen, O. K. (2017) · Circulation · doi:10.1161/circulationaha.116.022622 · Cited by 52
Mofsen, A. M., Rodebaugh, T. L., Nicol, G. E., Depp, C. A., Miller, J. P., & Lenze, E. J. (2019) · JMIR Mental Health · doi:10.2196/11845 · Cited by 51
Type 2 diabetes: RENAAL and IDNT–the emergence of new treatment options
Sica, D. A., & Bakris, G. L. (2002) · The Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2002.00749.x · Cited by 49
Telomere Homeostasis: Interplay with Magnesium
Maguire, D., Neytchev, O., Talwar, D., McMillan, D., & Shiels, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010157 · Cited by 50
Sanam, K., Bhatia, V., Bajaj, N. S., Gaba, S., Morgan, C. J., Fonarow, G. C., Butler, J., Deedwania, P., Prabhu, S. D., Wu, W.-C., et al. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.05.008 · Cited by 50
Self-citationBone-muscle crosstalk under physiological and pathological conditions
Dong, Y., Yuan, H., Ma, G., & Cao, H. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05331-y · Cited by 52
Interventions for weight loss in people with chronic kidney disease who are overweight or obese
Conley, M. M., McFarlane, C. M., Johnson, D. W., Kelly, J. T., Campbell, K. L., & MacLaughlin, H. L. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013119.pub2 · Cited by 49
Big Heart Data: Advancing Health Informatics Through Data Sharing in Cardiovascular Imaging
Suinesiaputra, A., Medrano-Gracia, P., Cowan, B. R., & Young, A. A. (2015) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2014.2370952 · Cited by 45
Van Guilder, G. P., Pretorius, M., Luther, J. M., Byrd, J. B., Hill, K., Gainer, J. V., & Brown, N. J. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.102574 · Cited by 42
Nakamura, K., Nakagawa, H., Murakami, Y., Kitamura, A., Kiyama, M., Sakata, K., Tsuji, I., Miura, K., Ueshima, H., & Okamura, T. (2015) · Kidney International · doi:10.1038/ki.2015.212 · Cited by 43
Renal nerves in physiology, pathophysiology and interoception
Evans, L. C., Dayton, A., & Osborn, J. W. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00893-3 · Cited by 46
Knudsen, S. H., & Pedersen, B. K. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0642-1 · Cited by 41
Fletcher, R. A., Jongs, N., Chertow, G. M., McMurray, J. J. V., Arnott, C., Jardine, M. J., Mahaffey, K. W., Perkovic, V., Rockenschaub, P., Rossing, P., et al. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000248 · Cited by 40
Acute Kidney Injury and Adverse Outcomes of Critical Illness: Correlation or Causation?
Girling, B. J., Channon, S. W., Haines, R. W., & Prowle, J. R. (2020) · Clinical Kidney Journal · doi:10.1093/ckj/sfz158 · Cited by 40
McCormack, T., Dent, R., & Blagden, M. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12881 · Cited by 39
Saglimbene, V., Palmer, S. C., Ruospo, M., Natale, P., Maione, A., Nicolucci, A., Vecchio, M., Tognoni, G., Craig, J. C., Pellegrini, F., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018040443 · Cited by 39
Nakanishi, T., & Kuragano, T. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae051 · Cited by 39
Suzuki, T., Agarwal, S. K., Deo, R., Sotoodehnia, N., Grams, M. E., Selvin, E., Calkins, H., Rosamond, W., Tomaselli, G., Coresh, J., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.07.004 · Cited by 38
Catalá-López, F., Aleixandre-Benavent, R., Caulley, L., Hutton, B., Tabarés-Seisdedos, R., Moher, D., & Alonso-Arroyo, A. (2020) · Trials · doi:10.1186/s13063-019-3944-9 · Cited by 38
First-line diuretics versus other classes of antihypertensive drugs for hypertension
Reinhart, M., Puil, L., Salzwedel, D. M., & Wright, J. M. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008161.pub3 · Cited by 38
Norman, J., Fu, M., Ekman, I., Björck, L., & Falk, K. (2018) · European Journal of Cardiovascular Nursing · doi:10.1177/1474515117715843 · Cited by 36
Willis, M., Nilsson, A., Kellerborg, K., Ball, P., Roe, R., Traina, S., Beale, R., & Newell, I. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00968-x · Cited by 36
Battaggia, A., Donzelli, A., Font, M., Molteni, D., & Galvano, A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0124587 · Cited by 36
Teramoto, K., Nadruz Junior, W., Matsushita, K., Claggett, B., John, J. E., Skali, H., Solomon, S., Cheng, S., & Shah, A. M. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.14833 · Cited by 36
Avins, A. L., Pressman, A., Ackerson, L., Rudd, P., Neuhaus, J., & Vittinghoff, E. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1477-8 · Cited by 33
Wu, H.-Y., Peng, C.-L., Chen, P.-C., Chiang, C.-K., Chang, C.-J., Huang, J.-W., Peng, Y.-S., Tu, Y.-K., Chu, T.-S., Hung, K.-Y., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0177654 · Cited by 33
Jain, A. B., & Lai, V. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01628-0 · Cited by 32
Petrera, A., Gassenhuber, J., Ruf, S., Gunasekaran, D., Esser, J., Shahinian, J. H., Hübschle, T., Rütten, H., Sadowski, T., & Schilling, O. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0907-8 · Cited by 32
McFarlane, S. I., Shin, J. J., Rundek, T., & Bigger, J. T. (2003) · Current Diabetes Reports · doi:10.1007/s11892-003-0070-5 · Cited by 28
Weir, M. R., Slee, A., Sun, T., Balis, D., Oh, R., de Zeeuw, D., & Perkovic, V. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfaa133 · Cited by 31
Helping patients with ESRD and earlier stages of CKD to quit smoking
Formanek, P., Salisbury-Afshar, E., & Afshar, M. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.01.057 · Cited by 31
Ortega, A., Gil-Cayuela, C., Tarazón, E., García-Manzanares, M., Montero, J. A., Cinca, J., Portolés, M., Rivera, M., & Roselló-Lletí, E. (2016) · PLOS ONE · doi:10.1371/journal.pone.0160168 · Cited by 30
Vascular Dysfunction, Oxidative Stress, and Inflammation in Chronic Kidney Disease
Nowak, K. L., Jovanovich, A., Farmer-Bailey, H., Bispham, N., Struemph, T., Malaczewski, M., Wang, W., & Chonchol, M. (2020) · Kidney360 · doi:10.34067/kid.0000962019 · Cited by 30
Miele, E. M., Headley, S. A. E., Germain, M., Joubert, J., Herrick, S., Milch, C., Evans, E., Cornelius, A., Brewer, B., Taylor, B., et al. (2017) · Clinical Kidney Journal · doi:10.1093/ckj/sfx006 · Cited by 30
The Prevalence and Prognosis of Resistant Hypertension in Patients with Heart Failure
Jin, C.-N., Liu, M., Sun, J.-P., Fang, F., Wen, Y.-N., Yu, C.-M., & Lee, A. P.-W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114958 · Cited by 29
Quantifying representativeness in randomized clinical trials using machine learning fairness metrics
Qi, M., Cahan, O., Foreman, M. A., Gruen, D. M., Das, A. K., & Bennett, K. P. (2021) · JAMIA Open · doi:10.1093/jamiaopen/ooab077 · Cited by 27
Hattori, K., Sakaguchi, Y., Oka, T., Asahina, Y., Kawaoka, T., Doi, Y., Hashimoto, N., Kusunoki, Y., Yamamoto, S., Yamato, M., et al. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000425 · Cited by 27
Management of hypertension in patients with chronic kidney disease
Hamrahian, S. M. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0739-9 · Cited by 26
Physiopathology of Phosphate Disorders
Portales-Castillo, I., Rieg, T., Khalid, S. B., Nigwekar, S. U., & Neyra, J. A. (2023) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2022.12.011 · Cited by 26
Attenuation of SARS-CoV-2 infection by losartan in human kidney organoids
Rahmani, W., Chung, H., Sinha, S., Bui-Marinos, M. P., Arora, R., Jaffer, A., Corcoran, J. A., Biernaskie, J., & Chun, J. (2022) · iScience · doi:10.1016/j.isci.2022.103818 · Cited by 25
Seidu, S., Kunutsor, S. K., Topsever, P., & Khunti, K. (2022) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.303 · Cited by 25
Ku, E., Tighiouart, H., McCulloch, C. E., Inker, L. A., Adingwupu, O. M., Greene, T., Estacio, R. O., Woodward, M., de Zeeuw, D., Lewis, J. B., et al. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000426 · Cited by 24
Effect of irbesartan on nitrotyrosine generation in non-hypertensive diabetic patients
Ceriello, A., Assaloni, R., Da Ros, R., Maier, A., Quagliaro, L., Piconi, L., Esposito, K., & Giugliano, D. (2004) · Diabetologia · doi:10.1007/s00125-004-1487-3 · Cited by 24
FGF23 in chronic kidney disease: Bridging the heart and anemia
Figurek, A., Rroji, M., & Spasovski, G. (2023) · Cells · doi:10.3390/cells12040609 · Cited by 22
Lundy, A.-L. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3066 · Cited by 19
Araújo, I., Marques, F., André, S., Araújo, M., Marques, S., Ferreira, R., Moniz, P., Proença, M., Borrego, P., & Fonseca, C. (2018) · Sleep and Breathing · doi:10.1007/s11325-017-1607-1 · Cited by 18
Uzu, T., Araki, S.-I., Kashiwagi, A., Haneda, M., Koya, D., Yokoyama, H., Kida, Y., Ikebuchi, M., Nakamura, T., Nishimura, M., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0164936 · Cited by 18
Heart Failure With Preserved Ejection Fraction: Prevention and Management
Cilia, L., Saeed, A., Ganga, H. V., & Wu, W.-C. (2019) · American Journal of Lifestyle Medicine · doi:10.1177/1559827617695219 · Cited by 18
Artificial intelligence–guided precision treatment of chronic kidney disease–mineral bone disorder
Gaweda, A. E., Lederer, E. D., & Brier, M. E. (2022) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12843 · Cited by 18
Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions
Tramontano, D., Bini, S., Maiorca, C., Di Costanzo, A., Carosi, M., Castellese, J., Arizaj, I., Commodari, D., Covino, S., Sansone, G., et al. (2025) · Drugs · doi:10.1007/s40265-025-02158-0 · Cited by 17
Chen, J., Hamm, L. L., Bundy, J. D., Kumbala, D. R., Bodana, S., Chandra, S., Chen, C.-S., Starcke, C. C., Guo, Y., Schaefer, C. M., et al. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02020220 · Cited by 16
Controlled dietary phosphate loading in healthy young men elevates plasma phosphate and FGF23 levels
Gerber, J. S., Arroyo, E. M. P., Pastor, J., Correia, M., Rudloff, S., Moe, O. W., Egli-Spichtig, D., Mohebbi, N., & Wagner, C. A. (2025) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-024-03046-4 · Cited by 15
Cardiovascular risk reduction in African Americans: Current concepts and controversies
Ferdinand, K. C. (2016) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2016.2 · Cited by 14
Yeung, M. H. Y., Leung, K. L., Choi, L. Y., Yoo, J. S., Yung, S., So, P.-K., & Wong, C.-M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.777395 · Cited by 14
Gaweda, A. E., McBride, D. E., Lederer, E. D., & Brier, M. E. (2021) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00159.2020 · Cited by 13
Angiotensin-Converting Enzyme Inhibition and Parathyroid Hormone Secretion
Zaheer, S., Brown, J. M., Connors, M., Williams, J. S., Adler, G. K., & Vaidya, A. (2017) · International Journal of Endocrinology · doi:10.1155/2017/4138783 · Cited by 12
Beddhu, S., Boucher, R. E., Sun, J., Balu, N., Chonchol, M., Navaneethan, S., Chertow, G. M., Townsend, R., Haley, W., Cheung, A. K., et al. (2021) · BMC Nephrology · doi:10.1186/s12882-021-02260-x · Cited by 10
Chen, P.-M., Wada, T., & Chiang, C.-K. (2017) · Clinical and Experimental Nephrology · doi:10.1007/s10157-016-1290-8 · Cited by 10
Rehan, H. S., Grover, A., & Hungin, A. P. S. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0715-4 · Cited by 9
Epigenome overlap measure (EPOM) for comparing tissue/cell types based on chromatin states
Li, W. V., Razaee, Z. S., & Li, J. J. (2016) · BMC Genomics · doi:10.1186/s12864-015-2303-9 · Cited by 10
Ichikawa, D., Kawarazaki, W., Saka, S., Kanaoka, T., Ohnishi, H., Arima, H., & Shibata, S. (2025) · Hypertension Research · doi:10.1038/s41440-025-02146-7 · Cited by 10
Hanon (2017) · doi:10.1111/jch.13053 · Cited by 10
Pharmacological interventions effective in improving exercise capacity in heart failure
Vitale, C., Spoletini, I., & Rosano, G. M. (2018) · Cardiac failure review · doi:10.15420/cfr.2018:8:2 · Cited by 9
Zhang, J., Tong, A., Dai, Y., Niu, J., Yu, F., & Xu, F. (2019) · The Journal of Clinical Hypertension · doi:10.1111/jch.13598 · Cited by 5
Figueroa, A. E., Roy, N., Millan-Ferro, A., Silva, P. S., & Rosas, S. E. (2023) · Ethnicity and Disease · doi:10.18865/1683 · Cited by 4
ACADEMIE Study Investigators, Imaizumi, S., Shiga, Y., Ogawa, M., Sako, H., Nagata, Y., Matsunaga, A., Shirotani, T., Hoshino, F., Yahiro, E., et al. (2019) · Heart and Vessels · doi:10.1007/s00380-018-1286-2 · Cited by 3
Metadata
- Authors
- Ahmed, A., Jorna, T., & Bhandari, S.
- Venue
- Nephron
- Publisher
- S. Karger AG
- Published
- 2016
- Volume
- 133
- Issue
- 3
- Pages
- 147-158
- ISSN
- 1660-8151 (ISSN-L)
- 2235-3186
- OpenAlex
- W2475261460
- Cited by
- 11,717
- References
- 170
- FWCI
- 957.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.